A Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early Diagnosis and Prognostication.

International journal of translational medicine (Basel, Switzerland) Pub Date : 2024-12-06 DOI:10.3390/ijtm4040050

Martin Tobi, Harvinder Talwar, Noreen F Rossi, Warren Lockette, Benita McVicker

{"title":"A Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early Diagnosis and Prognostication.","authors":"Martin Tobi, Harvinder Talwar, Noreen F Rossi, Warren Lockette, Benita McVicker","doi":"10.3390/ijtm4040050","DOIUrl":null,"url":null,"abstract":"Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions.Background/objectives: Recently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications.Methods: We have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication.Results: These InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means.Conclusions: The FERAD (ferritin-fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.","PeriodicalId":520354,"journal":{"name":"International journal of translational medicine (Basel, Switzerland)","volume":"4 4","pages":"726-739"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931686/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of translational medicine (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ijtm4040050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions.

Background/objectives: Recently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications.

Methods: We have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication.

Results: These InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means.

Conclusions: The FERAD (ferritin-fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.

查看原文本刊更多论文

使用先天免疫系统生物标志物组织癌症星座的实用格式：对早期诊断和预测的影响。

癌症发现的目的是确定一种特定的癌症类型，以便进行特定的治疗干预。背景/目的：最近，类似的免疫检查点疗法已经成功地应用于几种癌症类型，为其他具有实际应用的免疫破坏性干预开辟了领域。方法：我们已经发现了一种先天免疫系统（InImS）生物标志物，它允许表征相关癌症亚型和异常值，这可能有助于诊断、治疗和预后。结果：这些InImS生物标志物与PD-L1治疗结果相关，并且可能通过饮食方式被操纵。结论：FERAD（铁蛋白-粪便p87）和绝对中性粒细胞/淋巴细胞（aNLR）比率是两个这样的InImS生物标志物，我们在此表明，它们允许发现诊断和预后模式，正如本研究所证明的那样。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of translational medicine (Basel, Switzerland)

自引率

0.00%

发文量